Propranolol Hydrochloride
FDA-approved product (tablet, oral), marketed as Hemangeol, Inderal, Inderal La and 3 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Angina pectoris
- Cardiac arrhythmia
- Cardiovascular disease
- Coronary atherosclerosis
- Hemangioma
- Hypertension
- Migraine disorder
- Stroke
- Wolff-Parkinson-White Syndrome
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Beta blocking agents, non-selective
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA15.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli20.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae8.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Propranolol Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects
NCT02256722 · start 2005-10
Registered record
- Registry ID
- NCT02256722
- Conditions
- Healthy
- Interventions
- KUC 7483 CL; Bisoprolol; Propranolol; Acipimox; Salmeterol
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-10
- Completion
- Not recorded
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionKUC 7483 CL; Bisoprolol; Propranolol; Acipimox +1 morePhasePhase 1Registry statusCompletedAnalysis of Atropine and Propranolol Induced Changes
NCT00251602 · start 2003-03
Registered record
- Registry ID
- NCT00251602
- Conditions
- Healthy
- Interventions
- Atropine; Propranolol; Normal Saline
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2003-03
- Completion
- 2012-08
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionAtropine; Propranolol; Normal SalinePhasePhase 1Registry statusCompletedAssessment of Mechanisms of Improved Wound Healing
NCT00673309 · start 2000-07
Registered record
- Registry ID
- NCT00673309
- Conditions
- Burns
- Interventions
- Stable Isotope Infusion study; Insulin High Dose; oxandrolone; Propranolol; Growth Hormone; Insulin Low Dose; IGF-1/IGFBP-3; Itraconazole; Growth Hormone and Propranolol; Oxandrolone and Propranolol; Placebo or Control
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2000-07
- Completion
- 2013-04
- Enrolment
- 644
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBurnsInterventionStable Isotope Infusion study; Insulin High Dose; oxandrolone; Propranolol +7 morePhasePhase 2 / Phase 3Registry statusCompletedEffectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2
NCT00158132 · start 1999-09
Registered record
- Registry ID
- NCT00158132
- Conditions
- Cocaine-Related Disorders
- Interventions
- Propranolol; Amantadine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1999-09
- Completion
- 2006-02
- Enrolment
- 199
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCocaine-Related DisordersInterventionPropranolol; Amantadine; PlaceboPhasePhase 2Registry statusCompletedBeta-Blocker Heart Attack Trial (BHAT)
NCT00000492 · start 1977-09
Registered record
- Registry ID
- NCT00000492
- Conditions
- Arrhythmia; Cardiovascular Diseases; Coronary Disease; Death, Sudden, Cardiac; Heart Diseases; Myocardial Infarction; Myocardial Ischemia; Ventricular Fibrillation
- Interventions
- propranolol
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1977-09
- Completion
- 1981-10
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArrhythmia; Cardiovascular Diseases; Coronary Disease; Death, Sudden, Cardiac +4 moreInterventionpropranololPhasePhase 3Registry statusCompleted